Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study

PURPOSE: The objective of this study was to evaluate the safety and efficacy of immune checkpoint inhibitor (ICI) plus anlotinib as third-line treatment in extensive-stage small cell lung cancer (ES-SCLC). METHODS: A total of 120 patients with ES-SCLC who were admitted to Shandong Cancer Hospital be...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Qing, Li, Yan, Zhang, Wenjie, Wang, Chen, Yang, Shengjie, Guo, Qisen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article – Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800903/
https://www.ncbi.nlm.nih.gov/pubmed/34797416
http://dx.doi.org/10.1007/s00432-021-03858-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800903/
https://www.ncbi.nlm.nih.gov/pubmed/34797416
http://dx.doi.org/10.1007/s00432-021-03858-2

Ejemplares similares